Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2013

Market: Pharmaceuticals and Healthcare

Global, 40 pages report, published by Global Markets Direct

Keywords : Respiratory Tract Inflammatory Disorders Therapeutic Products under Development, Key Players in Respiratory Tract Inflammatory Disorders Therapeutics, Respiratory Tract Inflammatory Disorders Pipeline Overview, Respiratory Tract Inflammatory Disorders Pipeline, Respiratory Tract Inflammatory Disorders Pipeline Assessment

Report ThumbnailSeptember-2013
Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2013

Summary

Global Markets Direct’s, 'Respiratory Tract Inflammatory Disorders - Pipeline Review, H2 2013', provides an overview of the indication’s therapeutic pipeline. This report provides information on the therapeutic development for Respiratory Tract Inflammatory Disorders, complete with latest updates, and special features on late-stage and discontinued projects. It also reviews key players involved in the therapeutic development for Respiratory Tract Inflammatory Disorders. Respiratory Tract Inflammatory Disorders - Pipeline Review, Half Year is built using data and information sourced from Global Markets Direct’s proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Direct’s team.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data for the indicated disease.

Scope

- A snapshot of the global therapeutic scenario for Respiratory Tract Inflammatory Disorders.
- A review of the Respiratory Tract Inflammatory Disorders products under development by companies and universities/research institutes based on information derived from company and industry-specific sources.
- Coverage of products based on various stages of development ranging from discovery till registration stages.
- A feature on pipeline projects on the basis of monotherapy and combined therapeutics.
- Coverage of the Respiratory Tract Inflammatory Disorders pipeline on the basis of route of administration and molecule type.
- Key discontinued pipeline projects.
- Latest news and deals relating to the products.

Reasons to buy

- Identify and understand important and diverse types of therapeutics under development for Respiratory Tract Inflammatory Disorders.
- Identify emerging players with potentially strong product portfolio and design effective counter-strategies to gain competitive advantage.
- Plan mergers and acquisitions effectively by identifying players of the most promising pipeline.
- Devise corrective measures for pipeline projects by understanding Respiratory Tract Inflammatory Disorders pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline.
  • List of Figures
  • Number of Products under Development for Respiratory Tract Inflammatory Disorders, H2 2013 7
  • Products under Development for Respiratory Tract Inflammatory Disorders - Comparative Analysis, H2 2013 8
  • Products under Development by Companies, H2 2013 9
  • Products under Investigation by Universities/Institutes, H2 2013 10
  • Late Stage Products, H2 2013 11
  • Discovery and Pre-Clinical Stage Products, H2 2013 12
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Route of Administration, H2 2013 21
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Molecule Type, H2 2013 23
  • Assessment by Stage and Molecule Type, H2 2013 24
  • List of Tables
  • Number of Products Under Development for Respiratory Tract Inflammatory Disorders, H2 2013 7
  • Products under Development for Respiratory Tract Inflammatory Disorders - Comparative Analysis, H2 2013 8
  • Number of Products under Development by Companies, H2 2013 9
  • Number of Products under Investigation by Universities/Institutes, H2 2013 10
  • Comparative Analysis by Late Stage Development, H2 2013 11
  • Comparative Analysis by Discovery and Pre-Clinical Stage Development, H2 2013 12
  • Products under Development by Companies, H2 2013 13
  • Products under Investigation by Universities/Institutes, H2 2013 14
  • DBV Technologies, H2 2013 15
  • Verona Pharma Plc, H2 2013 16
  • Pharmagenesis, Inc., H2 2013 17
  • Cellmid Ltd, H2 2013 18
  • GlycoMar Limited, H2 2013 19
  • Assessment by Monotherapy Products, H2 2013 20
  • Assessment by Stage and Route of Administration, H2 2013 22
  • Assessment by Stage and Molecule Type, H2 2013 24
  • Respiratory Tract Inflammatory Disorders Therapeutics - Drug Profile Updates 35
  • Respiratory Tract Inflammatory Disorders Therapeutics - Dormant Products 36
  • Table of Contents
  • Table of Contents 2
  • List of Tables 4
  • List of Figures 4
  • Introduction 5
  • Global Markets Direct Report Coverage 5
  • Respiratory Tract Inflammatory Disorders Overview 6
  • Therapeutics Development 7
  • An Overview of Pipeline Products for Respiratory Tract Inflammatory Disorders 7
  • Respiratory Tract Inflammatory Disorders Therapeutics under Development by Companies 9
  • Respiratory Tract Inflammatory Disorders Therapeutics under Investigation by Universities/Institutes 10
  • Late Stage Products 11
  • Comparative Analysis 11
  • Discovery and Pre-Clinical Stage Products 12
  • Comparative Analysis 12
  • Respiratory Tract Inflammatory Disorders Therapeutics - Products under Development by Companies 13
  • Respiratory Tract Inflammatory Disorders Therapeutics - Products under Investigation by Universities/Institutes 14
  • Companies Involved in Respiratory Tract Inflammatory Disorders Therapeutics Development 15
  • DBV Technologies 15
  • Verona Pharma Plc 16
  • Pharmagenesis, Inc. 17
  • Cellmid Ltd 18
  • GlycoMar Limited 19
  • Respiratory Tract Inflammatory Disorders - Therapeutics Assessment 20
  • Assessment by Monotherapy Products 20
  • Assessment by Route of Administration 21
  • Assessment by Molecule Type 23
  • Drug Profiles 25
  • NAIPs - Drug Profile 25
  • Product Description 25
  • Mechanism of Action 25
  • R&D Progress 25
  • hu-91 - Drug Profile 26
  • Product Description 26
  • Mechanism of Action 26
  • R&D Progress 26
  • Wilvent - Drug Profile 28
  • Product Description 28
  • Mechanism of Action 28
  • R&D Progress 28
  • COVXPB-21 - Drug Profile 29
  • Product Description 29
  • Mechanism of Action 29
  • R&D Progress 29
  • GLY-145 - Drug Profile 30
  • Product Description 30
  • Mechanism of Action 30
  • R&D Progress 30
  • GLY-079 - Drug Profile 31
  • Product Description 31
  • Mechanism of Action 31
  • R&D Progress 31
  • PH-5 - Drug Profile 32
  • Product Description 32
  • Mechanism of Action 32
  • R&D Progress 32
  • Hyaluronan Signaling Antagonists - Drug Profile 33
  • Product Description 33
  • Mechanism of Action 33
  • R&D Progress 33
  • SPA-0355 - Drug Profile 34
  • Product Description 34
  • Mechanism of Action 34
  • R&D Progress 34
  • Respiratory Tract Inflammatory Disorders Therapeutics - Drug Profile Updates 35
  • Respiratory Tract Inflammatory Disorders Therapeutics - Dormant Products 36
  • Respiratory Tract Inflammatory Disorders - Product Development Milestones 37
  • Featured News & Press Releases 37
  • Jan 15, 2013: DBV Technologies And INRA Receive Funding To Develop Pediatric Bronchiolitis Vaccine 37
  • May 22, 2012: ProtAffin Presents New Preclinical Data Of PA401 At American Thoracic Society Conference 37
  • Jan 02, 2012: Orchid Pharma Reports Successful Completion Of Phase I Study Of OCID 2987 38
  • Appendix 39
  • Methodology 39
  • Coverage 39
  • Secondary Research 39
  • Primary Research 39
  • Expert Panel Validation 39
  • Contact Us 40
  • Disclaimer 40

Please select a license type

Share

Related Products

Global Markets DirectRespiratory Tract Inflammatory Disorders - Pipeline Review, H2 2013Product ThumbnailRespiratory Tract Inflammatory Disorders - Pipeline Review, H2 2013, Industry ReportProduct #: 113350
GlobalData
TeleResearch
Global Markets Direct
GBI Research
MarketsandMarkets
MicroMarketMonitor
PayPal Acceptance Mark
SSL Certificate
Copyright © 2017 Global Market Analyst. All Rights Reserved